Daniel Palanker, PhD, a professor of ophthalmology at Stanford Medicine and co-senior author of the study, expressed the profound significance of this achievement, stating, "All previous attempts to provide vision with prosthetic devices resulted in basically light sensitivity, not really form vision. We are the first to provide form vision." This remarkable feat is the culmination of decades of dedicated scientific effort, involving numerous prototypes, extensive animal testing, and an initial human trial, demonstrating the persistence and innovation driving this medical advancement. The research was further bolstered by the expertise of José-Alain Sahel, MD, professor of ophthalmology at the University of Pittsburgh School of Medicine, and Frank Holz, MD, of the University of Bonn in Germany, who served as the lead author, highlighting the global collaborative nature of this scientific endeavor.

The PRIMA system is elegantly designed with two core components working in tandem: an advanced pair of smart glasses equipped with a miniature camera, and a wireless chip surgically implanted at the back of the eye, specifically within the retina. The camera captures visual information from the environment and transmits it wirelessly to the retinal implant using infrared light. The implant then intelligently converts these infrared signals into electrical impulses. These electrical signals act as a sophisticated substitute for the damaged or degenerated photoreceptor cells in the retina, which are normally responsible for detecting light and relaying visual data to the brain. This ingenious method bypasses the diseased photoreceptors entirely, stimulating the remaining healthy retinal neurons to process and transmit visual information.

The genesis of the PRIMA project can be traced back two decades to Dr. Palanker’s innovative thinking. While engaged in research using ophthalmic lasers to treat various eye disorders, he conceived of a novel approach. "I realized we should use the fact that the eye is transparent and deliver information by light," he explained, a visionary concept that has now materialized into a functional reality. The device envisioned in 2005 has now transitioned from theoretical concept to a device that "works in patients remarkably well," underscoring the successful translation of scientific ideas into tangible patient benefits.

Participants in the latest clinical trial suffered from an advanced stage of age-related macular degeneration (AMD) known as geographic atrophy. This debilitating condition progressively destroys central vision, a process that affects over 5 million people worldwide and stands as the leading cause of irreversible blindness among older adults. In AMD, the critical light-sensitive photoreceptor cells in the macula, the central part of the retina responsible for sharp, detailed vision, deteriorate. This loss leaves individuals with only limited peripheral vision, severely impacting their ability to perform daily tasks. However, a crucial aspect of this condition is that many of the retinal neurons responsible for processing visual information often remain intact, even as the photoreceptors degrade. The PRIMA implant masterfully capitalizes on these surviving neural pathways.

Measuring a mere 2 by 2 millimeters, the implant is strategically placed in the area of the retina where photoreceptors have been lost. A key design element is its responsiveness to infrared light, emitted by the glasses, rather than visible light. "The projection is done by infrared because we want to make sure it’s invisible to the remaining photoreceptors outside the implant," Dr. Palanker elaborated. This critical distinction ensures that the artificial vision generated by the implant does not interfere with the patient’s natural, albeit limited, peripheral vision.

This thoughtful design allows patients to experience a synergistic combination of their existing natural peripheral vision and the newly restored artificial central vision. This dual visual input significantly enhances their ability to navigate their environment, orient themselves, and move with greater confidence and independence. "The fact that they see simultaneously prosthetic and peripheral vision is important because they can merge and use vision to its fullest," Palanker noted, emphasizing the integrated nature of the restored sight. Furthermore, the PRIMA implant is photovoltaic, meaning it generates its own electrical current solely from light. This self-sustaining power source eliminates the need for external power sources or cumbersome cables extending outside the eye, a significant improvement over earlier generations of artificial eye devices. This wireless and internal operation also enhances safety and user comfort.

The impact of the PRIMA system on participants’ lives is profoundly evident in their renewed ability to read. The study encompassed 38 patients, all over the age of 60, who had geographic atrophy and vision worse than 20/320 in at least one eye. Following implantation of the chip in one eye, patients began using the smart glasses after a period of four to five weeks. While some individuals could discern patterns immediately, all participants demonstrated consistent improvements in their visual acuity over several months of dedicated training. Dr. Palanker drew a parallel to the rehabilitation process required for cochlear implants, stating, "It may take several months of training to reach top performance — which is similar to what cochlear implants require to master prosthetic hearing."

The results of the one-year trial were overwhelmingly positive. Of the 32 patients who completed the study, a remarkable 27 were able to read, and 26 achieved what is defined as clinically meaningful improvement in visual acuity, meaning they could read at least two additional lines on a standard eye chart. On average, participants experienced an improvement of five lines on the eye chart, with one individual achieving an extraordinary 12-line improvement. The participants integrated the prosthesis into their daily routines, successfully using it to read books, decipher food labels, and recognize subway signs. The smart glasses offered crucial digital enhancements, including adjustable contrast and brightness, and a magnification capability of up to 12 times, empowering users to adapt their vision to various tasks and environments. User satisfaction was also high, with two-thirds of participants reporting medium to high levels of satisfaction with the device. While side effects were noted in 19 participants, including ocular hypertension, peripheral retinal tears, and subretinal hemorrhage, these were generally not life-threatening and resolved within two months, underscoring the overall safety profile of the implant.

Looking towards the future, the PRIMA device is poised for further advancements. Currently, the vision provided is black-and-white, lacking intermediate shades. However, Dr. Palanker is actively developing software to introduce a full range of grayscale vision. This development is particularly crucial for enhancing face recognition, a capability that patients have expressed a strong desire for, ranking it second only to reading. "Number one on the patients’ wish list is reading, but number two, very close behind, is face recognition. And face recognition requires grayscale," he explained.

Moreover, researchers are engineering next-generation chips designed to offer significantly higher resolution vision. The current resolution is limited by the size of the pixels on the chip, which are 100 microns wide, with 378 pixels per chip. A new version, already showing promise in trials with rats, features pixels as small as 20 microns wide, boasting an impressive 10,000 pixels per chip. This dramatic increase in pixel density is expected to yield a substantial improvement in visual clarity. Dr. Palanker estimates that a chip with 20-micron pixels could restore a patient’s vision to 20/80, and with the aid of electronic zoom, potentially achieve near 20/20 vision. The future also holds the potential to test the PRIMA device for other forms of blindness caused by photoreceptor loss, broadening its therapeutic reach. "This is the first version of the chip, and resolution is relatively low," Palanker acknowledged. "The next generation of the chip, with smaller pixels, will have better resolution and be paired with sleeker-looking glasses."

The groundbreaking research was a collaborative effort involving a multitude of institutions, including the University of Bonn, Germany; Hôpital Fondation A. de Rothschild, France; Moorfields Eye Hospital and University College London; Ludwigshafen Academic Teaching Hospital; University of Rome Tor Vergata; Medical Center Schleswig-Holstein, University of Lübeck; L’Hôpital Universitaire de la Croix-Rousse and Université Claude Bernard Lyon 1; Azienda Ospedaliera San Giovanni Addolorata; Centre Monticelli Paradis and L’Université d’Aix-Marseille; Intercommunal Hospital of Créteil and Henri Mondor Hospital; Knappschaft Hospital Saar; Nantes University; University Eye Hospital Tübingen; University of Münster Medical Center; Bordeaux University Hospital; Hôpital National des 15-20; Erasmus University Medical Center; University of Ulm; Science Corp.; University of California, San Francisco; University of Washington; University of Pittsburgh School of Medicine; and Sorbonne Université. Funding for this transformative study was generously provided by Science Corp., the National Institute for Health and Care Research, Moorfields Eye Hospital National Health Service Foundation Trust, and University College London Institute of Ophthalmology, underscoring the collective commitment to advancing vision restoration technologies.